Hospital
Concord Hospital-Laconia
Concord Hospital-Laconia was paid $9.25M by Medicaid between Jan 2018 and Nov 2024, across 215 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoCONCORD HOSPITAL-LACONIA
LACONIA, NH 03246
LACONIA, NH 03246
33aNPI1053495234assigned 10/25/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.25M
24GClaims369,597
24DCodes billed215
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Hampshire
Rank by total paid#6 of 9
Median peer was paid$10.80M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 106,503 | $2.08M | |
| 2019 | 100,101 | $2.22M | |
| 2020 | 92,754 | $2.47M | |
| 2021 | 32,117 | $900K | |
| 2022 | 30,303 | $1.25M | |
| 2023 | 5,662 | $242K | |
| 2024incomplete | 2,157 | $82K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 10,309 | 7,942 | $1.81M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 9,648 | 6,973 | $1.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 6,410 | 4,184 | $1.01M |
| G0378 | Hospital observation service, per hour | 7.5% | 2,088 | 773 | $694K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 1,972 | 1,464 | $298K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.8% | 26,786 | 13,176 | $261K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 3,055 | 2,439 | $246K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 2,316 | 1,594 | $227K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 9,986 | 2,605 | $159K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 4,929 | 3,054 | $135K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 485 | 370 | $128K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 3,300 | 1,883 | $126K |
203 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 3,603 | $109K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.1% | 924 | $105K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 4,361 | $97K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,086 | $92K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 407 | $84K |
| J3490 | Unclassified drugs | <1% | 27,883 | $83K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,692 | $83K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,991 | $79K |
| 80053 | Comprehensive metabolic panel | <1% | 14,683 | $70K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,576 | $60K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,450 | $58K |
| 80050 | General health panel | <1% | 7,149 | $55K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,514 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,504 | $50K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,367 | $45K |
| 96376 | <1% | 1,849 | $44K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,535 | $39K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 958 | $39K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 469 | $39K |
| 76830 | Ultrasound, transvaginal | <1% | 561 | $37K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,475 | $37K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,190 | $37K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 520 | $33K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,308 | $33K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,391 | $32K |
| 97161 | <1% | 775 | $29K | |
| 80061 | Lipid panel | <1% | 2,823 | $26K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 171 | $25K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,331 | $23K |
| 84484 | <1% | 5,530 | $23K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,203 | $21K |
| 97162 | <1% | 676 | $21K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,313 | $20K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,722 | $20K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 314 | $19K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,168 | $18K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,605 | $17K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 154 | $17K |
| 82947 | <1% | 4,180 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,634 | $17K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,977 | $17K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 745 | $16K |
| 97035 | <1% | 2,095 | $16K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,397 | $14K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,842 | $14K |
| 72100 | <1% | 774 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 680 | $14K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,013 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,052 | $13K |
| 83690 | <1% | 3,379 | $13K | |
| 73030 | <1% | 752 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,080 | $12K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 182 | $12K |
| 93971 | <1% | 210 | $12K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 221 | $12K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 603 | $12K |
| 87186 | <1% | 2,367 | $12K | |
| 83880 | <1% | 739 | $11K | |
| 84702 | <1% | 896 | $11K | |
| 73630 | <1% | 507 | $11K | |
| 80305 | <1% | 2,225 | $10K | |
| 87040 | <1% | 1,807 | $10K | |
| 85610 | <1% | 5,775 | $10K | |
| 73610 | <1% | 614 | $10K | |
| 83605 | <1% | 1,683 | $9K | |
| 73130 | <1% | 440 | $8K | |
| 84703 | <1% | 1,591 | $8K | |
| 83735 | <1% | 2,111 | $8K | |
| 81001 | <1% | 4,886 | $8K | |
| 87088 | <1% | 3,319 | $8K | |
| 82728 | <1% | 814 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 747 | $7K |
| 97803 | <1% | 499 | $7K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,464 | $7K |
| 86803 | <1% | 722 | $7K | |
| 87806 | <1% | 424 | $7K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 663 | $7K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,204 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 929 | $7K |
| 86850 | <1% | 964 | $7K | |
| 82805 | <1% | 485 | $6K | |
| 74018 | <1% | 434 | $6K | |
| 81025 | <1% | 1,546 | $6K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 158 | $6K |
| 97165 | <1% | 166 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,638 | $6K |
| 87077 | <1% | 1,077 | $6K | |
| 87070 | <1% | 1,120 | $6K | |
| 73562 | <1% | 380 | $6K | |
| 94060 | <1% | 172 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 856 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,853 | $5K |
| 73560 | <1% | 330 | $5K | |
| 85379 | <1% | 995 | $5K | |
| 87081 | <1% | 1,153 | $5K | |
| 76801 | <1% | 61 | $5K | |
| 73110 | <1% | 232 | $5K | |
| 85027 | <1% | 1,108 | $5K | |
| 84439 | <1% | 680 | $4K | |
| 73502 | <1% | 387 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 949 | $4K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 16 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,902 | $4K |
| 86140 | <1% | 1,290 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 853 | $4K |
| 20610 | <1% | 226 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,808 | $3K |
| 94726 | <1% | 126 | $3K | |
| 81003 | <1% | 3,663 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 422 | $3K |
| 82607 | <1% | 372 | $3K | |
| 87205 | <1% | 990 | $3K | |
| 99001 | <1% | 512 | $3K | |
| 85730 | <1% | 793 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,829 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 315 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 747 | $2K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 147 | $2K |
| 85652 | <1% | 1,347 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 27 | $2K |
| 82375 | <1% | 554 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 61 | $2K |
| 94729 | <1% | 148 | $2K | |
| 86317 | <1% | 188 | $2K | |
| 71250 | <1% | 13 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 75 | $2K |
| 86900 | <1% | 940 | $2K | |
| 86901 | <1% | 926 | $2K | |
| 93017 | <1% | 54 | $1K | |
| 86592 | <1% | 424 | $1K | |
| 72040 | <1% | 75 | $1K | |
| 96367 | <1% | 91 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 257 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,236 | $1K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 20 | $1K |
| 97802 | <1% | 38 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 694 | $1K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 715 | $1K |
| 90715 | <1% | 158 | $1K | |
| 36416 | <1% | 1,243 | $1K | |
| 95117 | <1% | 265 | $969.18 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 705 | $941.65 |
| 88304 | <1% | 56 | $941.58 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 15 | $926.22 |
| 86618 | <1% | 93 | $903.46 | |
| 73564 | <1% | 34 | $875.20 | |
| 87340 | <1% | 118 | $852.23 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 774 | $753.47 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $724.74 |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 33 | $698.79 |
| 83550 | <1% | 120 | $695.03 | |
| 87449 | <1% | 106 | $676.17 | |
| 83540 | <1% | 149 | $632.33 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 86 | $603.37 |
| 97113 | <1% | 28 | $600.78 | |
| 76642 | <1% | 39 | $582.33 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 356 | $485.26 |
| 83010 | <1% | 59 | $444.00 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 58 | $406.66 |
| 97166 | <1% | 16 | $399.64 | |
| 86762 | <1% | 37 | $387.07 | |
| 84403 | <1% | 14 | $332.42 | |
| 82950 | <1% | 81 | $330.34 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 17 | $323.19 |
| 87147 | <1% | 80 | $320.65 | |
| G0008 | Administration of influenza virus vaccine | <1% | 288 | $319.43 |
| 84153 | <1% | 32 | $304.04 | |
| 87807 | <1% | 35 | $288.30 | |
| 83516 | <1% | 22 | $287.40 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 36 | $276.40 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 99 | $258.72 |
| 82565 | <1% | 87 | $255.08 | |
| 72170 | <1% | 13 | $228.28 | |
| 82550 | <1% | 68 | $226.41 | |
| 84100 | <1% | 57 | $209.45 | |
| 36600 | <1% | 19 | $202.14 | |
| 86696 | <1% | 12 | $200.75 | |
| 90686 | <1% | 163 | $192.89 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 22 | $157.63 |
| 80320 | <1% | 31 | $149.00 | |
| 86695 | <1% | 12 | $136.73 | |
| 80164 | <1% | 17 | $136.51 | |
| 86038 | <1% | 19 | $129.94 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 89 | $129.19 |
| 84520 | <1% | 64 | $123.98 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 34 | $106.65 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 21 | $104.96 |
| 83655 | <1% | 12 | $99.78 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 94 | $95.92 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 81 | $72.54 |
| J1815 | Injection, insulin, per 5 units | <1% | 27 | $71.20 |
| 82043 | <1% | 14 | $65.18 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 78 | $65.14 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 18 | $58.34 |
| 90674 | <1% | 58 | $48.67 | |
| 90662 | <1% | 47 | $42.70 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 20 | $41.25 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 37 | $34.91 |
| A4565 | Slings | <1% | 17 | $27.17 |
| 85018 | <1% | 12 | $19.41 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 25 | $18.45 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 348 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 321 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSLOANE, SCOTT (CHIEF FINANCIAL OFFICER)
Parent organizationCONCORD HOSPITAL-LACONIA
| Provider | Location | Paid |
|---|---|---|
| Concord Hospital, INC. | Concord, NH | $28.77M |
| Concord Hospital-Franklin | Franklin, NH | $7.28M |
| Concord Hospital, INC. | Concord, NH | $3.74M |
| Concord Hospital-Franklin | Franklin, NH | $3.61M |
| Concord Hospital-Laconia | Laconia, NH | $2.92M |
| Concord Hospital-Franklin | Franklin, NH | $2.72M |
| Concord Hospital-Laconia | Laconia, NH | $2.53M |
| Concord Hospital, INC. | Concord, NH | $2.48M |
| Concord Hospital-Laconia | Laconia, NH | $109K |
| Concord Hospital-Laconia | Laconia, NH | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.